We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth?
Read MoreHide Full Article
Key Takeaways
EMBC readies Q4 results after prior-quarter gains from product strength and regional trends.
EMBC's U.S. sales saw temporary boosts from rebate adjustments and order timing that may reverse in Q4.
International growth led by Latin America and Asia, while China's decline and product momentum shape Q4.
Embecta Corp. (EMBC - Free Report) is set to release fourth-quarter fiscal 2025 results on Nov. 25, before the market opens.
Here’s a brief review of the company’s performance leading up to this announcement.
Factors That Might Have Shaped EMBC’s Q4 Performance
During the previous quarter in the United States, the company delivered solid growth, aided by a weaker prior-year comparison, changes in rebate reserves and favorable order timing. That said, the lift from early orders is only temporary and should reverse in the fiscal fourth quarter.
Turning to the International business, sales growth in the previous quarter was driven primarily by Latin America and Asia, benefiting from a favorable comparison to the prior year. However, the growth was partially offset by a year-over-year decline in China. We expect this trend to have continued in the to-be-reported quarter as well.
From the perspective of product segments, pen needles, syringes, safety products, and contract manufacturing all delivered strong growth in the fiscal third quarter, providing a solid boost to the company’s overall revenues. The year-over-year increase in pen needle revenues was largely the result of higher product volumes, as pricing remained essentially unchanged compared to the prior year. In contrast, syringe revenues grew solid, driven mainly by stronger pricing rather than volume. Safety products also delivered growth primarily due to better pricing. We expect these momentums to have continued in the fiscal fourth quarter as well.
During the fiscal third quarter, the company achieved several important milestones. It completed the global transition to its own ERP system, shared service operations and distribution infrastructure in India (the last market still operating on legacy BD systems). Embecta also made significant progress on its U.S. and Canada brand transition initiative, which remains on track to be largely finished by the end of fiscal 2025.
In addition, EMBC signed multiple contracts and received several purchase orders from pharmaceutical partners to co-package Embecta pen needles with potential generic GLP-1 therapies. It also continued advancing efforts to broaden access to appropriately sized GLP-1 retail packaging designed for weekly injection treatments. We expect these developments to have contributed to the company’s top-line growth in fiscal fourth quarter.
EMBC’s Zacks Rank and Key Picks
Embecta currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are BrightSpring Health Services (BTSG - Free Report) , Medpace Holdings (MEDP - Free Report) and Alzamend Neuro (ALZN - Free Report) .
BrightSpring Health Services, currently carrying a Zacks Rank #1 (Strong Buy), is expected to release fourth-quarter 2025 results soon. Per the Zacks Consensus Estimate, BTSG’s fourth-quarter EPS is expected to surge 54.6% from the year-ago reported figure. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace, sporting a Zacks Rank #1 at present, is expected to release fourth-quarter 2025 results soon. Per the Zacks Consensus Estimate, the company’s third-quarter EPS is anticipated to increase 13.9% from the year-ago quarter figure.
Alzamend Neuro, currently carrying a Zacks Rank #2 (Buy), is expected to release second-quarter fiscal 2026 results soon. Per the Zacks Consensus Estimate, the company’s third-quarter EPS is expected to increase 76.9% from the year-ago quarter figure.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth?
Key Takeaways
Embecta Corp. (EMBC - Free Report) is set to release fourth-quarter fiscal 2025 results on Nov. 25, before the market opens.
Here’s a brief review of the company’s performance leading up to this announcement.
Factors That Might Have Shaped EMBC’s Q4 Performance
During the previous quarter in the United States, the company delivered solid growth, aided by a weaker prior-year comparison, changes in rebate reserves and favorable order timing. That said, the lift from early orders is only temporary and should reverse in the fiscal fourth quarter.
Turning to the International business, sales growth in the previous quarter was driven primarily by Latin America and Asia, benefiting from a favorable comparison to the prior year. However, the growth was partially offset by a year-over-year decline in China. We expect this trend to have continued in the to-be-reported quarter as well.
From the perspective of product segments, pen needles, syringes, safety products, and contract manufacturing all delivered strong growth in the fiscal third quarter, providing a solid boost to the company’s overall revenues. The year-over-year increase in pen needle revenues was largely the result of higher product volumes, as pricing remained essentially unchanged compared to the prior year. In contrast, syringe revenues grew solid, driven mainly by stronger pricing rather than volume. Safety products also delivered growth primarily due to better pricing. We expect these momentums to have continued in the fiscal fourth quarter as well.
During the fiscal third quarter, the company achieved several important milestones. It completed the global transition to its own ERP system, shared service operations and distribution infrastructure in India (the last market still operating on legacy BD systems). Embecta also made significant progress on its U.S. and Canada brand transition initiative, which remains on track to be largely finished by the end of fiscal 2025.
Embecta Corp. Price and EPS Surprise
Embecta Corp. price-eps-surprise | Embecta Corp. Quote
In addition, EMBC signed multiple contracts and received several purchase orders from pharmaceutical partners to co-package Embecta pen needles with potential generic GLP-1 therapies. It also continued advancing efforts to broaden access to appropriately sized GLP-1 retail packaging designed for weekly injection treatments. We expect these developments to have contributed to the company’s top-line growth in fiscal fourth quarter.
EMBC’s Zacks Rank and Key Picks
Embecta currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are BrightSpring Health Services (BTSG - Free Report) , Medpace Holdings (MEDP - Free Report) and Alzamend Neuro (ALZN - Free Report) .
BrightSpring Health Services, currently carrying a Zacks Rank #1 (Strong Buy), is expected to release fourth-quarter 2025 results soon. Per the Zacks Consensus Estimate, BTSG’s fourth-quarter EPS is expected to surge 54.6% from the year-ago reported figure. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace, sporting a Zacks Rank #1 at present, is expected to release fourth-quarter 2025 results soon. Per the Zacks Consensus Estimate, the company’s third-quarter EPS is anticipated to increase 13.9% from the year-ago quarter figure.
Alzamend Neuro, currently carrying a Zacks Rank #2 (Buy), is expected to release second-quarter fiscal 2026 results soon. Per the Zacks Consensus Estimate, the company’s third-quarter EPS is expected to increase 76.9% from the year-ago quarter figure.